 |
| |
| Mar-01-19 | Downgrade |
Northland Capital |
Outperform → Market Perform |
|
|
| Jul-17-18 | Resumed |
Stifel |
Buy |
$72 |
|
| Jul-16-18 | Downgrade |
BofA/Merrill |
Neutral → Underperform |
|
|
| Nov-10-17 | Reiterated |
Stifel |
Buy |
$57 → $39 |
|
| Nov-10-17 | Reiterated |
Stifel |
Buy |
$39 → $57 |
|
| Dec-29-16 | Initiated |
Northland Capital |
Outperform |
$40 |
|
| May-03-16 | Initiated |
JMP Securities |
Mkt Outperform |
|
|
| Mar-01-16 | Reiterated |
Stifel |
Buy |
$69 → $57 |
|
| Mar-01-16 | Reiterated |
Mizuho |
Neutral |
$28 → $29 |
|
| Jan-25-16 | Reiterated |
Mizuho |
Neutral |
$42 → $28 |
|
| Nov-11-15 | Upgrade |
Mizuho |
Underperform → Neutral |
$45 → $42 |
|
| Oct-19-15 | Reiterated |
Wunderlich |
Buy |
$70 → $50 |
|
| Oct-14-15 | Initiated |
BofA/Merrill |
Neutral |
$35 |
|
| Sep-21-15 | Initiated |
Stifel |
Buy |
$69 |
|
| Aug-11-15 | Downgrade |
Mizuho |
Neutral → Underperform |
$45 |
|
| Aug-11-15 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Jul-27-15 | Reiterated |
Wunderlich |
Buy |
$55 → $70 |
|
| Jun-09-15 | Initiated |
Wunderlich |
Buy |
$55 |
|
| Mar-10-15 | Downgrade |
Mizuho |
Buy → Neutral |
$14 |
|
| Mar-03-15 | Reiterated |
Mizuho |
Buy |
$32 → $50 |
|
|
|
| May-21-19 11:15PM | Intrexon Corp (XON) CEO Randal J Kirk Bought $2.9 million of Shares GuruFocus.com |
| 11:41AM | Weekly CEO Buys Highlight GuruFocus.com |
| May-20-19 07:22PM | Cramer's lightning round: I feel bad if you own Intrexon It's a loser CNBC |
| 02:55PM | Intrexon CEO buys up more company shares American City Business Journals |
| May-15-19 08:15PM | Intrexon Corp (XON) CEO Randal J Kirk Bought $5.5 million of Shares GuruFocus.com +6.29% |
| May-13-19 07:30AM | Intrexon to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference PR Newswire |
| May-10-19 08:34AM | Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues Zacks |
| May-09-19 04:10PM | Intrexon Reports First Quarter 2019 Financial Results PR Newswire |
| May-02-19 04:30PM | AquaBounty Technologies, Inc. Announces Results for the Quarter Ended March 31, 2019, and Company Update GlobeNewswire |
| 04:05PM | Intrexon to Release First Quarter 2019 Financial Results on May 9th PR Newswire |
| 01:53PM | Heres What Hedge Funds Think Of Intrexon Corp (XON) Insider Monkey |
| 10:32AM | Analysts Estimate Intrexon (XON) to Report a Decline in Earnings: What to Look Out for Zacks |
| Apr-29-19 07:30AM | Intrexon and Xogenex Present at American Society of Gene and Cell Therapy Annual Meeting PR Newswire |
| Apr-25-19 04:05PM | Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland PR Newswire |
| Apr-17-19 04:45PM | AquaBounty Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares GlobeNewswire -12.43% |
| Apr-16-19 10:59AM | Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises Zacks +6.51% |
| 07:30AM | Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper PR Newswire |
| Apr-15-19 06:30AM | Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy GlobeNewswire |
| Apr-10-19 07:30AM | Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference PR Newswire |
| Apr-09-19 04:00PM | AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock GlobeNewswire -5.94% |
| 07:30AM | Oxitec Advances Self-Limiting Fall Armyworm Control Solution to Next Phase of Development PR Newswire |
| Apr-08-19 08:28AM | Why Intrexon Stock Dropped 34% in March Motley Fool |
| Apr-04-19 09:55PM | AquaBounty Technologies, Inc. Announces Pricing of $5.75 Million Public Offering of Common Stock GlobeNewswire |
| 04:08PM | AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire |
| Apr-03-19 07:30AM | Intrexon Intensifies Focus on Healthcare, Forms Two Units and Streamlines Management PR Newswire |
| Apr-02-19 07:00AM | AquaBounty Technologies, Inc. Environment and Climate Change Canada Approves Rollo Bay Facility for Commercial Production of AquAdvantage Salmon GlobeNewswire |
| Mar-30-19 09:30AM | Why Is Intrexon (XON) Down 34% Since Last Earnings Report? Zacks |
| Mar-22-19 04:00AM | Next Green Wave's Nursery Botticelli(TM) Research & Development Program Begins Newsfile -6.77% |
| Mar-21-19 04:01PM | AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock GlobeNewswire +5.69% |
| Mar-19-19 06:00AM | AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire |
| Mar-18-19 04:00PM | AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire |
| Mar-12-19 07:20AM | Jim Cramer Shares His Thoughts On Ambarella, Centurylink, Chipotle And More Benzinga |
| Mar-08-19 03:19PM | AquaBounty Technologies, Inc. - FDA Lifts Import Alert on AquAdvantage Salmon GlobeNewswire |
| Mar-07-19 05:00PM | AquaBounty Technologies, Inc. Results for the year ended December 31, 2018 GlobeNewswire +9.11% |
| Mar-05-19 06:41PM | Edited Transcript of XON earnings conference call or presentation 28-Feb-19 10:30pm GMT Thomson Reuters StreetEvents +21.26% |
| 04:01PM | Here's What Caused Intrexon's 21% Rally Today Motley Fool |
| 07:45AM | Market Trends Toward New Normal in Ritchie Bros. Auctioneers, Empire State Realty Trust, Synergy Resources, IQVIA, Intrexon, and Denbury Resources Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire |
| Mar-04-19 04:47PM | Here's Why Intrexon Crashed (Again) Today Motley Fool -18.18% |
| 04:03PM | Intrexon, Surterra Wellness Collaborate On Plant Propagation For Cannabis Cultivation Benzinga |
| 07:30AM | Intrexon and Surterra Wellness to Collaborate on Botticelli Next Generation Plant Propagation for Cannabis Cultivation PR Newswire |
| Mar-01-19 09:16AM | Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4 Zacks -36.51% |
| 01:40AM | Intrexon Corp (XON) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| Feb-28-19 04:15PM | Intrexon Reports 2018 Fourth Quarter and Year End Financial Results PR Newswire |
| Feb-27-19 07:30AM | Intrexon to Showcase Differentiated Methane Bioconversion Platform at Upcoming Petroleum Industry Events PR Newswire |
| Feb-21-19 07:30AM | Intrexon to Announce Fourth Quarter 2018 Financial Results on February 28th PR Newswire |
| Feb-20-19 09:00AM | Intrexon's Subsidiary Precigen to Present at the SVB Leerink 8th Annual Global Healthcare Conference PR Newswire |
| Feb-14-19 08:20AM | Consolidated Research: 2019 Summary Expectations for Sabre, Groupon, Intrexon, Comfort Systems, O'Reilly Automotive, and Ellington Financial Fundamental Analysis, Key Performance Indications GlobeNewswire |
| Feb-11-19 07:30AM | Precigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients PR Newswire |
| Jan-25-19 09:44AM | Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds Zacks |
| Jan-21-19 09:21AM | Can This Stock Go From Potential Zika Virus Savior to Marijuana Kingpin? Motley Fool |
| Jan-16-19 04:19PM | Intrexon Signs Licensing Agreement with Next Green Wave Zacks |
| Jan-15-19 11:22AM | RETRANSMISSION: Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon Newsfile |
| 07:30AM | Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon Newsfile |
| 07:30AM | Intrexon Partners with Next Green Wave to Advance Intrexon's Botticelli Next Generation Plant Propagation Platform into Development for Cannabis PR Newswire |
| Jan-08-19 08:00AM | Investing in a New Age of Cannabinoid Production for Cost Efficiency and Scalability GlobeNewswire |
| Jan-02-19 07:30AM | Intrexon Announces Presentations at Upcoming Investor Conferences PR Newswire +9.33% |
| Dec-31-18 07:30AM | Precigen to Debut Portfolio at Investor Event during the 37th Annual J.P. Morgan Healthcare Conference PR Newswire |
| Dec-24-18 07:30AM | Precigen to Host Conference Call to Provide Business Updates PR Newswire |
| Dec-21-18 12:35PM | Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndrome (MDS) PR Newswire |
| 07:30AM | Exemplar Genetics and Mayo Clinic Launch Joint Venture Focused on Development of Human Liver Cells to Advance Medical Research PR Newswire |
| Dec-20-18 03:23PM | AquaBounty Technologies, Inc.: Issuance of USDA labeling rule GlobeNewswire |
| 07:42AM | Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon PR Newswire |
| 07:30AM | Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program PR Newswire |
| Dec-18-18 07:30AM | Intrexon and AquaBounty Receive Regulatory Exemption in Development of Gene Edited Tilapia for More Sustainable Production PR Newswire -6.65% |
| Dec-14-18 08:41AM | Do Options Traders Know Something About Intrexon (XON) Stock We Don't? Zacks |
| Dec-08-18 09:30AM | Why Is Intrexon (XON) Down 31.5% Since Last Earnings Report? Zacks |
| Nov-30-18 07:35AM | New Research: Key Drivers of Growth for Intrexon, Graham, The Walt Disney, Toyota Motor, Atlas Air Worldwide, and SITO Mobile Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire |
| Nov-29-18 02:31PM | Oil recovers after dropping below $50 Yahoo Finance Video |
| Nov-28-18 07:30AM | Oxitec Transitioning Friendly Self-limiting Mosquitoes to 2nd Generation Technology Platform, Paving Way to New Scalability, Performance and Cost Breakthroughs PR Newswire +6.70% |
| 07:30AM | AquaBounty appoints Sylvia Wulf as Chief Executive Officer GlobeNewswire |
| Nov-21-18 01:42PM | Not business as usual: Rockville biotechs new CEO wants to turn things around American City Business Journals |
| Nov-09-18 02:08PM | Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3 Zacks -18.53% |
| 07:00AM | Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and Intrexon ACCESSWIRE |
| Nov-08-18 11:16PM | Edited Transcript of XON earnings conference call or presentation 8-Nov-18 10:30pm GMT Thomson Reuters StreetEvents |
| 04:10PM | Intrexon Announces Third Quarter 2018 Financial Results PR Newswire |
| 07:56AM | A Preview Of Intrexon's Q3 Earnings Benzinga |
| Nov-02-18 07:30AM | AquaBounty Technologies, Inc. Results for the quarter and nine months ended September 30, 2018 GlobeNewswire |
| Nov-01-18 03:37PM | Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp. PR Newswire +9.69% |
| 07:30AM | Intrexon to Announce Third Quarter 2018 Financial Results on November 8th PR Newswire |
| Oct-29-18 05:14PM | Bragar Eagel & Squire, P.C. is Investigating Intrexon Corporation (XON) on Behalf of Stockholders and Encourages XON Investors to Contact the Firm GlobeNewswire |
| 07:30AM | ActoBio Therapeutics Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes PR Newswire |
| Oct-25-18 06:50PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE |
| 10:43AM | SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intrexon Corporation (XON) ACCESSWIRE |
| Oct-24-18 07:30AM | Intrexon Announces the Formation of Bioinformatics Hub in Munich PR Newswire -15.37% |
| Oct-23-18 03:05PM | Gaithersburg biotech CEO to step down American City Business Journals |
| 08:40AM | Report: Exploring Fundamental Drivers Behind Q2, Badger Meter, Tiffany, Walgreens Boots Alliance, Intrexon, and Denali Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
| Oct-18-18 08:43AM | Oxitec to Develop 2nd Friendly Mosquito Strain Designed to Combat Malaria-Spreading Mosquitoes PR Newswire |
| Oct-16-18 05:28PM | AquaBounty receives construction loan to support development efforts at its Rollo Bay property GlobeNewswire +5.06% |
| 04:56PM | INVESTIGATION UPDATE for XON, APOG and ATASY: Levi & Korsinsky, LLP Reminds Investors of Investigations on Behalf of Shareholders GlobeNewswire |
| Oct-12-18 07:38PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON GlobeNewswire |
| Oct-09-18 07:00AM | Ziopharm and Precigen Redefine Relationships, Announce New License Agreement GlobeNewswire |
| Oct-03-18 09:15PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE |
| Sep-26-18 07:52PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE |
| Sep-25-18 03:00PM | Intrexons Latest Pitch: Were a Pot Stock Motley Fool -9.33% |
| 08:45AM | Implied Volatility Surging for Intrexon (XON) Stock Options Zacks |
| 08:00AM | Todays Research Reports on Stocks to Watch: Intrexon and Tilray ACCESSWIRE |
| 07:30AM | Ziopharm Oncology to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire |
| Sep-24-18 05:40PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON ACCESSWIRE +31.52% |
| 01:31PM | Merger Mania: Examining the Latest M&A News & Trends | Free Lunch Zacks |
| 11:42AM | Intrexon, Once a Fighter of Zika, Pivots to Join Pot Mania Bloomberg |
|
|
|
|
| Intrexon Corporation engage in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| KIRK RANDAL J | Chief Executive Officer | May 21 | Buy | 4.74 | 90,335 | 428,188 | 17,294,866 | May 21 08:05 PM | | KIRK RANDAL J | Chief Executive Officer | May 21 | Buy | 4.74 | 60,223 | 285,457 | 930,504 | May 21 08:07 PM | | KIRK RANDAL J | Chief Executive Officer | May 20 | Buy | 4.63 | 301,670 | 1,396,732 | 918,459 | May 21 08:07 PM | | KIRK RANDAL J | Chief Executive Officer | May 20 | Buy | 4.63 | 452,502 | 2,095,084 | 17,242,131 | May 21 08:05 PM | | KIRK RANDAL J | Chief Executive Officer | May 17 | Buy | 4.69 | 90,794 | 425,824 | 16,977,975 | May 21 08:05 PM | | KIRK RANDAL J | Chief Executive Officer | May 17 | Buy | 4.69 | 60,530 | 283,886 | 858,125 | May 21 08:07 PM | | KIRK RANDAL J | Chief Executive Officer | May 15 | Buy | 4.59 | 314,050 | 1,441,490 | 846,019 | May 15 05:38 PM | | KIRK RANDAL J | Chief Executive Officer | May 15 | Buy | 4.59 | 471,077 | 2,162,243 | 16,924,973 | May 15 05:36 PM | | KIRK RANDAL J | Chief Executive Officer | May 14 | Buy | 4.37 | 221,251 | 966,867 | 16,649,972 | May 15 05:36 PM | | KIRK RANDAL J | Chief Executive Officer | May 14 | Buy | 4.37 | 147,500 | 644,575 | 783,209 | May 15 05:38 PM | | KIRK RANDAL J | Chief Executive Officer | May 13 | Buy | 4.25 | 376,932 | 1,601,961 | 753,709 | May 15 05:38 PM | | KIRK RANDAL J | Chief Executive Officer | May 13 | Buy | 4.25 | 565,399 | 2,402,946 | 16,520,814 | May 15 05:36 PM | | KIRK RANDAL J | 10% Owner | Apr 03 | Sale | 0.65 | 95,241 | 61,907 | 62,342 | Apr 03 05:13 PM | | KIRK RANDAL J | 10% Owner | Apr 02 | Sale | 0.66 | 13,646 | 9,006 | 88,422 | Apr 03 05:13 PM | | KIRK RANDAL J | 10% Owner | Apr 01 | Sale | 0.67 | 41,678 | 27,924 | 92,159 | Apr 03 05:13 PM | | MITCHELL DEAN J | Director | Mar 12 | Option Exercise | 3.17 | 8,906 | 28,232 | 41,750 | Mar 12 07:11 PM | | Reed Thomas D. | Chief Science Officer | Mar 05 | Sale | 4.66 | 2,300 | 10,718 | 41,705 | Mar 06 09:07 PM | | Reed Thomas D. | Chief Science Officer | Mar 04 | Sale | 4.18 | 225,500 | 943,690 | 44,005 | Mar 06 09:07 PM | | ALVAREZ CESAR L | Director | Feb 19 | Option Exercise | 3.17 | 2,968 | 9,409 | 117,817 | Feb 21 04:46 PM | | Frank Steven | Director | Feb 12 | Option Exercise | 3.17 | 2,968 | 9,409 | 195,225 | Feb 14 04:41 PM | | Reed Thomas D. | Chief Science Officer | Feb 07 | Option Exercise | 3.17 | 2,969 | 9,412 | 96,280 | Feb 11 04:57 PM | | LIFFMAN JOEL D | SVP, Finance | Jan 04 | Sale | 7.03 | 3,725 | 26,187 | 85,541 | Jan 04 06:46 PM | | Reed Thomas D. | Chief Science Officer | Jan 03 | Sale | 7.07 | 2,944 | 20,816 | 79,537 | Jan 04 06:47 PM | | Perez Jeffrey Thomas | SVP, IP Affairs | Jan 03 | Sale | 7.07 | 3,514 | 24,846 | 18,789 | Jan 04 06:48 PM | | Lehr Donald P. | Chief Legal Officer | Jan 03 | Sale | 7.07 | 3,832 | 27,094 | 34,183 | Jan 04 06:48 PM | | Sterling Rick L. | Chief Financial Officer | Jan 03 | Sale | 7.07 | 3,514 | 24,846 | 80,873 | Jan 04 06:46 PM | | Sabzevari Helen | President, Precigen, Inc. | Jan 03 | Sale | 7.07 | 3,832 | 27,094 | 22,532 | Jan 04 06:46 PM | | Nimrodi Nir | Chief Business Officer | Jan 03 | Sale | 7.07 | 4,058 | 28,692 | 5,708 | Jan 04 06:45 PM | | Walsh Robert F. III | SVP, Energy & Fine Chem. | Jan 03 | Sale | 7.07 | 4,058 | 28,692 | 5,708 | Jan 04 06:46 PM | | Reed Thomas D. | Chief Science Officer | Dec 31 | Sale | 6.36 | 30,000 | 190,671 | 72,715 | Jan 03 05:56 PM | | LIFFMAN JOEL D | SVP, Finance | Oct 15 | Sale | 14.59 | 79,000 | 1,152,808 | 79,500 | Oct 17 07:51 PM | | Sabzevari Helen | President, Precigen, Inc. | Jul 18 | Sale | 14.54 | 8,402 | 122,165 | 16,598 | Jul 19 06:03 PM | | KIRK RANDAL J | Chief Executive Officer | Jul 03 | Buy | 13.37 | 7,479,431 | 99,999,992 | 15,937,319 | Jul 06 04:46 PM |
|
|
|
|
|
|
